Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Regulatory
  • Third Circuit Affirms Denial of Stelara Biosimilar Injunction
  • Regulatory

Third Circuit Affirms Denial of Stelara Biosimilar Injunction

Big Molecule Watch

As previously reported, litigation between Johnson Johnson and Janssen ("J J") and Samsung Bioepis ("Samsung") involving Samsung's Stelara biosimilar, PYZCHIVA (ustekinumab-ttwe) (previously known as

Immunology & Inflammation

Read full story

pharminent May 11, 2026 (Last updated: May 12, 2026)

Big Molecule Watch

As previously reported, litigation between Johnson Johnson and Janssen (“J J”) and Samsung Bioepis (“Samsung”) involving Samsung’s Stelara biosimilar, PYZCHIVA (ustekinumab-ttwe) (previously known as

Immunology & Inflammation

Read full story

Post navigation

Previous: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge
Next: Cellular Intelligence scoops up Novo’s Parkinson’s therapy

Related Stories

  • Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026
  • Regulatory

HHS appoints permanent FDA CBER, CDER heads

pharminent September 10, 2026
  • Regulatory

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

pharminent September 7, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.